https://www.prnewswire.com/news-releases/neurorx-announces-zyesami-aviptadil-rlf-100-met-the-primary-endpoint-of-its-phase-2b3-clinical-trial-and-also-demonstrated-a-meaningful-benefit-in-survival-from-critical-covid-19-301257291.html
New drug trial finished to treat CRITICAL COVID. 75% survival at 60 day mark in the most severe cases. Likely higher if treatment is started sooner since damage is already done once in critical condition. A covidians worst nightmare. No excuses left. Open it all up. Shut down the printers.
ETA recovery. Not just survival. Also significantly reduces hospitalization time.
New drug trial finished to treat CRITICAL COVID. 75% survival at 60 day mark in the most severe cases. Likely higher if treatment is started sooner since damage is already done once in critical condition. A covidians worst nightmare. No excuses left. Open it all up. Shut down the printers.
ETA recovery. Not just survival. Also significantly reduces hospitalization time.